Suven, Cohance aim to double combined business revenue to Rs 6,000 cr by FY29

Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and inorganic growth. The merger has received NSE and BSE approvals, with a shareholders meeting scheduled for November 28, 2024. The combined entity will focus on pharma CDMO, specialty chemicals CDMO, and APIs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ITczxfL
via IFTTT